Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Recombinant Human Parathyroid Hormone after Single- and Multiple-Dose Subcutaneous Administration in Healthy Chinese Volunteers-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Recombinant Human Parathyroid Hormone after Single- and Multiple-Dose Subcutaneous Administration in Healthy Chinese Volunteers

Published:2011-08-18 Issue:2 Volume:110 Page:154-161
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:

Author:

Liu Yani,Shi Shaojun,Wu Jianhong,Li Zhongfang,Zhou Xingqin,Zeng Fandian

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Reference30 articles.

1. National Institutes of Health (NIH) The NIH Osteoporosis and Related Bone Diseases - National Resource Center. Osteoporosis http://www.niams.nih.gov/health_Info/Bone/Osteoporosis/default.asp

2. Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis;Papapoulos;Nat Clin Pract Endocrinol Metab,2008

3. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window;Bilezikian;Curr Osteoporos Rep,2008

4. The use of PTH in the treatment of osteoporosis;Borba;Arq Bras Endocrinol Metabol,2010

5. Clinical use of teriparatide in the real world: initial insights;Miller;Endocr Pract,2004

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilarity Assessment of the Biosimilar Teriparatide Candidate and the Reference Drug in Healthy Subjects;Clinical Pharmacology in Drug Development;2023-01-29

2. Recombinant human parathyroid hormone (1–84) replacement therapy in a child with hypoparathyroidism;Bone;2021-03

3. Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers;Scientific Reports;2019-10-31

4. Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis;Pharmaceutics;2019-06-07

5. The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study;Osteoporosis International;2018-10-24